<div class="container">

<table style="width: 100%;"><tr>
<td>CI.RatioF</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>
1–2*alpha Fieller CI given point estimate, CV (, CVb) and n
</h2>

<h3>Description</h3>

<p>Utility function to calculate the
1–2α
Fieller confidence interval given the point estimate, 
CV (, CVb), and n for the parallel group and
2×2
crossover.
</p>


<h3>Usage</h3>

<pre><code class="language-R">CI.RatioF(alpha = 0.025, pe, CV, CVb, n, design = c("2x2", "parallel"))
</code></pre>


<h3>Arguments</h3>

<table>
<tr style="vertical-align: top;">
<td><code>alpha</code></td>
<td>

<p>Type I error probability, aka significance level.<br>
Defaults here to 0.025 because this function is intended for studies
with clinical endpoints. 
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>pe</code></td>
<td>

<p>Point estimate of T/R ratio.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>CV</code></td>
<td>

<p>Coefficient of variation as ratio (not percent). In case of <code>design="parallel"</code>
this is the CV of the total variability, in case of <code>design="2x2"</code>
the intra-subject CV.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>CVb</code></td>
<td>

<p>CV of the between-subject variability. Only necessary for
<code>design="2x2"</code>.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>n</code></td>
<td>

<p>Total number of subjects if a scalar is given.<br>
Number of subjects in (sequence) groups if given as vector.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>design</code></td>
<td>

<p>A character string describing the study design.<br><code>design="parallel"</code> or <code>design="2x2"</code> allowed for a
parallel two-group design or a classical TR|RT crossover design.
</p>
</td>
</tr>
</table>
<h3>Details</h3>

<p>The CV(within) and CVb(etween) in case of <code>design="2x2"</code> are
obtainedvia an appropriate ANOVA from the error term and from the
difference <code>(MS(subject within sequence)-MS(error))/2</code>.
</p>


<h3>Value</h3>

<p>Returns the
1–2α
confidence interval.
</p>


<h3>Note</h3>

<p>The function assumes an evaluation using un-transformed data.<br>
The function assumes equal variances in case of <code>design="parallel"</code>.<br>
The formula implemented covers balanced and unbalanced designs.<br><br>
Note that when the mean of the denominator of the ratio is close to zero, 
confidence intervals might be degenerated and are returned as <code>NA</code>. In such
a case a warning is issued.<br><br>
Whether the function vectorizes properly is not thoroughly tested.<br><br>
This function is intended for studies with clinical endpoints. In such
studies the 95% confidence intervals are usually used for equivalence 
testing. Therefore, alpha defaults here to 0.025 (see <abbr><span class="acronym">EMA</span></abbr> 2000).
</p>


<h3>Author(s)</h3>

<p>D. Labes
</p>


<h3>References</h3>

<p>Locke CS. <em>An exact confidence interval from untransformed data for the ratio of 
two formulation means.</em> J Pharmacokin Biopharm. 1984;12(6):649–55. <a href="https://doi.org/10.1007/BF01059558">doi:10.1007/BF01059558</a>
</p>
<p>Hauschke D, Steinijans VW, Pigeot I. <em>Bioequivalence Studies in Drug Development.</em> Chichester: John Wiley; 2007. Chapter 10. <a href="https://doi.org/10.1002/9780470094778.fmatter">doi:10.1002/9780470094778.fmatter</a>
</p>
<p>European Medicines Agency, Committee for Proprietary Medicinal Products. <em>Points to consider on switching between superiority and non-inferiority.</em> London, 27 July 2000. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-switching-between-superiority-and-non-inferiority_en.pdf">CPMP/EWP/482/99</a>
</p>


<h3>See Also</h3>

<p><code>CI.BE</code>, <code>power.RatioF</code>
</p>


<h3>Examples</h3>

<pre><code class="language-R"># 95% Fieller CI for the 2x2 crossover
CI.RatioF(pe = 0.95, CV = 0.3, CVb = 0.6, n = 32)
</code></pre>


</div>